Despite the introduction of new and better treatments, rapidly implemented in our countries, our registries uncover subgroups of patients that still...
The magnitude of OS benefit with upfront HDT is cytogenetics-dependent. Patients with high-risk cytogenetics should preferably receive upfront rather...
I risultati suggeriscono la potenziale utilità dell’analisi del cfDNA nel plasma del sangue periferico dei pazienti come biomarcatore rilevante per l...